title: Marketing and commercial distribution of ponatinib suspended following FDA request.
authors.forename: Stacey
authors.initials: S
authors.lastname: Small
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D040541:Marketing; D011724:Pyridazines / Q000009:adverse effects* / Q000627:therapeutic use; D056737:Safety-Based Drug Withdrawals; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D011724:Pyridazines; C545373:ponatinib